Insmed

Biotechnology

Insmed focuses on rare pulmonary diseases, with an approved therapy for nontuberculous mycobacterial lung disease. The company's inhaled liposomal amikacin represents innovative drug delivery for difficult-to-treat lung infections. Insmed exemplifies the growing focus on orphan diseases and specialty pharmaceuticals.

The Biology of Business

Sign up to be notified when the book is available to order.

Notify Me